The results of our study confirm that ctDNA analysis is a reliable and clinically useful tool to define the tumor molecular profile of ER+/HER2− patients with metastatic disease, which is essential to adequately treat those who have previously undergone endocrine therapy. The gene discussed is ESR1; the disease is metastatic neoplasm.